Plasma p-tau217 testing can help detect preclinical Alzheimer disease in cognitively unimpaired adults. Using it as a first-line screen followed by positron emission tomography or cerebrospinal fluid testing boosts accuracy, reduces false positives, and streamlines recruitment.